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Abstract 
In this study, we synthesised thiolated silica nanoparticles using 3-
mercaptopropyltrimethoxysilane and functionalised them with either 5 kDa methoxy 
polyethylene glycol maleimide (PEG) or 5 kDa alkyne-terminated poly(2-ethyl-2-oxazoline) 
(POZ). The main objectives of this study are to investigate the effects of pH on the size and 
ξ-potential of these nanoparticles and evaluate their mucoadhesive properties ex vivo using rat 
intestinal mucosa. The sizes of thiolated, PEGylated and POZylated silica nanoparticles were 
53 ± 1, 68 ± 1 and 59 ± 1 nm, respectively. The particle size of both thiolated and POZylated 
nanoparticles significantly increased at pH ≤ 2, whereas no size change was observed at pH 
2.5-9 for both these two types of nanoparticles. On the other hand, the size of PEGylated 
nanoparticles did not change over the studied pH range (1.5-9). Moreover, thiolated 
nanoparticles were more mucoadhesive in the rat small intestine than both PEGylated and 
POZylated nanoparticles. After 12 cycles of washing (with a total of 20 mL of phosphate 
buffer solution pH 6.8), a significantly greater amount of thiolated nanoparticles remained on 
the intestinal mucosa than FITC-dextran (non-mucoadhesive polymer, p < 0.005) and both 
PEGylated and POZylated nanoparticles (p < 0.05 both). However, both PEGylated and 
POZylated nanoparticles showed similar retention to FITC-dextran (p > 0.1 for both). Thus, 
this study indicates thiolated nanoparticles are mucoadhesive, whereas PEGylated and 
POZylated nanoparticles are non-mucoadhesive in the rat intestinal mucosa model. Each of 
these nanoparticles has potential applications in mucosal drug delivery. 
1. Introduction 
Oral drug delivery is the preferred administration route for most drugs, as it has several 
advantages over other routes, including better patient adherence (especially for chronic 
diseases) and possibilities for flexible dosing (Date et al., 2016). In addition, oral dosage 
forms generally cost less to manufacture than other formulations (e.g. injectable, eye drops 
and inhalators) as they do not require sterilisation (Yun et al., 2013; Date et al., 2016) or 
complex delivery device. However, about 70% of new drugs do not reach pre-clinical 
development due to low bioavailability resulting from poor oral absorption (Gao et al., 2013). 
Drug absorption in the gastrointestinal tract (GIT) is hampered by a number of physiological 
barriers, including the mucus, the harsh pH and digestive environment of the GIT, tight 
junctions, epithelial cells and sub-epithelial tissues (Lundquist & Artursson, 2016).  
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Mucus is a viscous gel secreted by goblet cells, which are found in various organs, including 
the eye (Kessler & Dartt, 1994), the GIT (Deplancke & Gaskins, 2001)  and the respiratory 
tract (Spicer et al., 1983). It consists mainly of water (~ 95%), alongside cross-linked and 
entangled mucin fibres, lipids,  proteins, salts, cellular debris and bacteria (Moghissi et al., 
1960; Bansil & Turner, 2006; Johansson et al., 2011; Leal et al., 2017)).  Mucus can be 
targeted using mucoadhesive drug delivery systems that adhere to this layer to prolong the 
residence time of the dosage forms, leading to sustained release of the loaded drugs and 
enhanced bioavailability compared to conventional non-mucoadhesive formulations 
(Bernkop-Schnürch, 2005; Khutoryanskiy, 2011).  
Several types of nanoparticles have been shown to have the potential as drug delivery system 
(Nguyen et al., 2016; Hu et al., 2017; Davoudi et al., 2018). Siew et al. (2012) developed 
nanoparticles based on mucoadhesive quaternary ammonium palmitoyl glycol chitosan. 
These nanoparticles enhanced the oral absorption of both hydrophilic (ranitidine) and 
hydrophobic drugs (griseofulvin and cyclosporine A). In separate studies, Bernkop-Schnürch 
and co-workers have developed thiolated polymers and shown their potential in the design of 
mucoadhesive nanoparticulate drug delivery systems (Dünnhaupt et al., 2011; Bonengel & 
Bernkop-Schnürch, 2014). Prego et al. (2006) designed chitosan nanocapsules to enhance the 
absorption of salmon calcitonin from intestine and prolong its action as a result of their 
mucoadhesive properties and strong interaction with the intestinal mucous membranes. 
Previously, Khutoryanskiy et al. have developed thiolated silica nanoparticles and 
demonstrated their mucoadhesive properties on ocular (Irmukhametova et al., 2011) and 
urinary bladder mucosa (Mun et al., 2016). They also demonstrated that these nanoparticles 
could be easily functionalised via fluorescent labelling, PEGylation and POZylation 
(introduction of polyethylene glycols and polyoxazolines, respectively) (Irmukhametova et 
al., 2011; Irmukhametova et al., 2012; Mun et al., 2014a; Mansfield et al., 2015; Mansfield et 
al., 2016). PEGylation of thiolated silica nanoparticles was found to reduce the retention of 
thiolated silica nanoparticles on the ocular (Irmukhametova et al., 2011) and urinary bladder 
mucosal surfaces (Mun et al., 2016). More recently, Mansfield et al. (2015; 2016) 
demonstrated that POZylation of these nanoparticles could enhance their penetration into 
porcine gastric mucosa.  
Clearly, the nature of the adhesion between two surfaces (here, the nanoparticles and the 
mucous membrane) is highly dependent on the properties of both (Smart, 2005; Varum et al., 
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2010; Khutoryanskiy, 2011). For example, we previously showed that thiolated and 
PEGylated silica nanoparticles were less retentive on the ocular surface compared to the 
urinary bladder mucosal surface (Irmukhametova et al., 2011; Mun et al., 2016). This 
difference in retention might be due to the rougher structure of the latter resulting in an 
increased contact area (Irmukhametova et al., 2011; Khutoryanskiy, 2011; Mun et al., 2016). 
To our knowledge, the mucoadhesion of our POZylated silica nanoparticles has never been 
studied. Therefore, in the present work, we sought to investigate the retentive properties of 
these silica nanoparticles in the rat intestinal mucosa. We further analysed the 
physicochemical properties of these nanoparticles, particularly their pH-stability profiles. 
2. Materials and methods 
2.1 Materials 
3-mercaptopropyltrimethoxysilane (MPTS), maleimide terminated methoxy poly(ethylene 
glycol) (PEG) 5 kDa, alkyne terminated poly(2-ethyl-2-oxazoline) (POZ) 5 kDa 
(polydispersity index, PDI ≤ 1.2), 5,5ʹ-dithiobis (2-nitrobenzoic acid) (DTNB), fluorescein 
isothiocyanate (FITC), medium molecular weight chitosan (degree of acetylation 26.1%, 124 
kDa), FITC-dextran (3.5-5 kDa) and triethyl amine (TEA) were purchased from Sigma-
Aldrich (Gillingham, UK). FITC-chitosan was made in house (Symonds et al., 2016a). 
Fluorescein-O-methacrylate (FMA), dimethyl sulfoxide (DMSO) and NaOH were purchased 
from Fisher Scientific (UK). Dialysis membrane with molecular cut-off 12-14 kDa was 
purchased from Medicell International Ltd., UK.  
2.2 Synthesis of thiolated silica nanoparticles 
Thiolated silica nanoparticles were synthesised according to a published method 
(Irmukhametova et al., 2011). In brief, 20 mL DMSO and 0.5 mL of 0.5 M NaOH solution were 
added to 0.75 mL MPTS. The mixture was continuously stirred and aerated for 24 hours at room 
temperature. Next, the nanoparticle suspensions were dialysed against deionised water (4 L, 8 
changes of water over 2 days) using the dialysis membrane. The purified nanoparticle 
suspensions were refrigerated at 4 °C until use. 
2.3 Synthesis of PEGylated and POZylated silica nanoparticles 
Thiolated silica nanoparticles were functionalised using two different polymers; PEG and 
POZ. To synthesise PEGylated nanoparticles, 100 mg PEG was added to 10 mL thiolated 
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nanoparticle suspension and the mixture was stirred for 24 hours at room temperature. To 
synthesise POZylated particles, 5 mL of thiolated nanoparticle suspension was diluted with 5 
mL DMSO and then 100 mg POZ was added to the diluted thiolated nanoparticles. To this 
mixture, 200 µL TEA was added to enhance the thiol-yne click reaction (Mansfield et al., 
2015). The reaction mixture was left for 24 hours with continuous stirring. The nanoparticles 
were purified by dialysis as described in section 2.2 and refrigerated at 4 °C until use.                                                                                               
2.4 Fluorescent labelling of nanoparticles 
Each of the thiolated, PEGylated and POZylated silica nanoparticle suspensions (5 mL) were 
diluted with DMSO (5 mL). To this, 2 mL (3.59 µmol) of 1.8 mM fluorescein-O-
methacrylate solution (in 1:1 deionised water: ethanol) and 200 µL TEA was added. The 
reaction mixture was stirred in the dark for 24 hours. Subsequently, the fluorescently labelled 
nanoparticles were purified (again in the dark) as described in section 2.2. 
2.5 Characterisation of nanoparticles 
The size and ξ-potential of the nanoparticles were measured using Zetasizer Nano-ZS 
(Malvern, UK). For the size measurements, the samples were diluted 1:100 with ultrapure 
water before analysis. A refractive index of 1.475 and an absorbance of 0.1 were used for all 
measurements. Measurements were conducted in triplicate for 10 seconds per run, with 12 
runs per reading at 25 °C. ξ-potential values were measured using DTS-1070 folded capillary 
tube cuvettes (Malvern, UK). Samples were measured using 3 repeats of 20 sub-runs per 
reading. At least 3 samples were measured and processed using the Smoluchowski model 
(Fκa = 1.50).  
Transmission electron microscopy (TEM) was conducted using a JEM-2100 PLUS Electron 
Microscope (JEOL, USA) at an accelerating voltage of 200 kV. Three drops of nanoparticle 
suspensions were placed on a carbon-coated copper grid and left for 1 minute before being 
loaded into the instrument. The morphology of the nanoparticles was investigated without 
any staining.  
2.6 Determination of thiol content 
Ellman’s assay was used to quantify the free thiol groups available on the surface of the 
nanoparticles. Initially, the nanoparticles were lyophilised using the Heto Power Dry LL 3000 
freeze-drier (Thermo Electron Corporation). The nanoparticles (3 mg) were suspended in 10 
mL phosphate buffer solution (0.5 M, pH 8). Then, 0.5 mL aliquots of nanoparticle 
 
 
 
  
 
 
   
5 
 
suspension was reacted with 0.5 mL DTNB (0.3 mg/mL) in the dark for 2 hours. Next, the 
product was centrifuged for 10 minutes at 13000 rpm (Sanyo, Micro Centaur, UK) and 200 
µL aliquots of supernatant was loaded into a 96 well-plate. The light absorbance was 
measured at 420 nm using an Epoch microplate reader (BioTek Instruments, Inc.). In order to 
obtain a calibration curve, serial solutions of L-cysteine HCl over the concentration range of 
0.634 to 0.004 µmol/mL were prepared and reacted with DTNB under the same conditions as 
the nanoparticles. Phosphate buffer solution (pH 8) was used as the blank control. Finally, the 
amount of free thiols per gram of the particles was calculated. 
2.7 FTIR spectroscopy 
FTIR spectra of the freeze-dried nanoparticles were recorded using a Spectrum 100 FTIR 
spectrophotometer (Perkin-Elmer, UK). The spectra were collected from an average of 4 
scans, with a resolution of 4 cm-1 over the range of 4000-650 cm-1. 
2.8 Thermogravimetric analysis (TGA) 
Freeze-dried samples were analysed for all three types of silica nanoparticles using the 
Q50 thermogravimetric analyser (TA Instruments, UK) equipped with nitrogen to provide an 
inert environment. The instrument was zeroed against an empty differential scanning 
calorimetry aluminium pan. The samples were placed in an aluminium pan and then in a 
platinum TGA pan and loaded into the instrument. The initial temperature was set at 35 °C 
and the thermal decomposition of the samples was studied between 35 and 500 °C, at 5 °C 
/minute heating rate. 
2.9 Fluorescence spectroscopy 
Fluorescently labelled nanoparticle suspensions were diluted (1:400-1:12,800) with PBS 
(pH 7.4). The fluorescence emission spectra were measured between 500 -700 nm (emission 
wavelength) using a fluorescence spectrometer (Cary Eclipse, Varian Inc., US) at 490 nm 
excitation wavelength. 
2.10 pH-stability study 
Unlabelled nanoparticle suspensions were diluted with ultrapure water (1:100, 60 mL and 40 
mL of the diluted nanoparticle suspensions were prepared for experiments of decreasing and 
increasing pH, respectively). The pH was adjusted using 1 M HCl or 1 M NaOH solutions. 
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Then at each pH point, the size and ξ-potential of the nanoparticles were measured as 
described in section 2.5.  
2.11 Determination of minimum detection limit of nanoparticles by fluorescence microscopy 
The minimum detection limit of the nanoparticles was determined by first measuring the 
concentration of fluorescently labelled thiolated nanoparticles by gravimetry (1.15 ± 0.20 
mg/mL; n = 3). This was performed by placing 1 mL of thiolated nanoparticles in a glass 
container and heating on a hotplate, initially at 100 °C for a few minutes, then at 75 °C. The 
sample was weighed periodically and re-heated until a constant weight was obtained, 
indicating complete drying of the nanoparticles. Then, serial suspensions of fluorescently 
labelled thiolated nanoparticles were prepared in deionised water over the concentration 
range of 0.004–0.533 mg/mL. Diluted thiolated nanoparticle suspensions (20 µL) were 
applied on 0.8 × 1.2 cm2 rat intestinal mucosa (tissues sample was used within 10 minutes of 
thawing). Fluorescent images were recorded using a fluorescence microscope (Leica 
Microsystems, UK) at 160 ms exposure time. The images were then analysed by ImageJ 
(National Institutes of Health, USA) and the coefficient of determination (R2) was calculated. 
2.12 Mucoadhesion study 
Fluorescence microscopy was used to investigate the mucoadhesion of the synthesised 
nanoparticles. A Leica MZ10F fluorescence microscope (Leica Microsystems, UK) with ET-
GFP filter, maximum excitation light intensity and 160 ms exposure time was used (in case of 
FITC-chitosan, however, 211 ms exposure time was used to compensate its poor fluorescence 
emission). In this study, freshly isolated small intestinal tissue from healthy 3 to 4 month-old 
Sprague Dawley female rats was used. The intestines were cut open to approximately 0.8 × 
1.2 cm2 and placed on a microscope slide. Fluorescence micrographs of the mucosal surface 
were taken as background fluorescence intensity. Thereafter, a 20 µL suspension of 
fluorescently labelled nanoparticles was placed on the intestinal mucosal surface and 
incubated for 5 minutes, before fluorescence micrographs were again recorded. The tissues 
were transferred to a sloped channel and washed with 1 mL or 5 mL of phosphate buffer 
solution (100 mM, pH 6.8, 37 ± 1 °C) for the total of 13 cycles. Fluorescence micrographs 
were recorded sequentially after each wash cycle. The images were analysed using the 
ImageJ software and normalised according to the following equation: 
𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 =
𝐼−𝐼𝑏
𝐼𝑜−𝐼𝑏
 × 100                     Equation (1), 
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where, I is the fluorescence intensity of a given tissue sample nanoparticles after each wash 
cycle, Ib is the background fluorescence intensity of that tissue sample, and Io is the initial 
fluorescence intensity of that sample (i.e. following nanoparticles incubation but preceding 
any wash cycle). Each tissue sample provided its own control for background fluorescence 
intensity. The experiments were performed in triplicate using tissues obtained from 3-4 rats, 
and the order in which each nanoparticle type was studied in any individual experiment was 
randomised. FITC-chitosan (1 mg/mL in 0.1 M acetic acid) and FITC-dextran (1 mg/mL in 
deionised water) were used as positive and negative controls, respectively. 
In addition, WO50 (Mun et al., 2016) and WO70 values were quantified. These values 
represent the amount of phosphate buffer solution necessary to attenuate the fluorescence 
intensity on the mucosal surface by 50% and 70%, respectively. The values were calculated 
by extrapolation of the average wash-off data using 6th order polynomial fitting and Wolfram 
Alpha (a computational knowledge engine). 
2.13. Statistical analysis 
Unless otherwise stated, all measurements were collected in triplicate and the data are 
expressed as mean ± standard deviation (SD). The data were analysed using the SPSS 
Statistics 21 program (IBM, US). The statistical significance of any difference between 
groups was determined using one-way analysis of variance (ANOVA) with the least 
significant difference (LSD) post-hoc test. Differences were considered statistically 
significant at p ˂ 0.05.  
3. Results and discussion 
 
3.1. Nanoparticles synthesis and characterisation 
Thiolated nanoparticles were synthesised via hydrolysis and subsequent condensation of the 
methoxysilane groups of MPTS, forming a cross-linked nanoparticle structure through Si-O-
Si and disulfide bonds. All nanoparticle samples exhibited acceptable PDI (PDI ˂ 0.2, as 
determined by DLS), with a single peak around the z-average of the particles (Fig. 1 and 
Table 1). Particles with PDI < 0.05 are highly monodisperse but rarely seen unless with 
standard nanoparticles. Nanoparticles with PDI ˃ 0.7 have generally very broad size 
distribution and not recommended to be sized using DLS technique. Thus, lower PDI 
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indicates higher homogeneity of the nanoparticles and vice versa  (Malvern Instruments Ltd., 
2011). The particle size increased in the order of thiolated < POZylated < PEGylated 
nanoparticles (Fig. 1 and Table 1).  
 
  
 
Fig. 1. Exemplar dynamic light scattering size distribution of thiolated, PEGylated and 
POZylated silica nanoparticles.  
 
Table 1  
Characteristics of unlabelled thiolated, PEGylated and POZylated silica nanoparticles 
(mean ± SD, n = 3); for size and ξ-potential measurement, the nanoparticles suspensions 
were diluted with ultrapure water (1:100). 
Types of 
particles 
Size (d-nm) PDI ξ-potential   
(mV) 
Conc.a 
(mg/mL) 
Free thiol 
content 
(µmol/g) 
Thiolated 53 ± 1 0.118 ± 0.012 
 
-42 ± 2 
 
 
  6 ± 2 368 ± 11 
 
PEGylated 68 ± 1 
 
0.128 ± 0.002 
 
-22 ± 3 
 
 
 
 13 ± 1 175 ± 2 
 
 
POZylated 59 ± 1 0.134 ± 0.014 
 
  -31 ± 4   5 ± 1 53 ± 18 
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The difference in particle size between each pair of nanoparticle type was statistically 
significant (p ˂ 0.05). The larger PEGylated and POZylated nanoparticles indicate successful 
grafting of the polymers onto the thiolated nanoparticles core. PEG 5 kDa contains 113 
repeating units of ethylene glycol (Mr= 44), whereas POZ 5 kDa consists of 50 repeating 
units of 2-ethyl-2-oxazoline (Mr=99). This means that the PEG chains were longer than the 
POZ chains, resulting in a thicker shell and thus larger particles (Mansfield, 2016). Another 
possible reason for the size discrepancy between PEG and POZ nanoparticles is related to the 
different spatial arrangement of PEG and POZ around the core nanoparticles. Typically, PEG 
molecules form long-brush or mushroom configurations. The former happens when the 
density of PEG on the surface of nanoparticles is high, while the latter occurs in cases of low 
surface coverage (Owens & Peppas, 2006). In contrast, POZ forms star-shaped structures 
(Rossegger et al., 2013). Also, it can be hypothesised that different polymer chain folding and 
relaxation behaviour in water may also contribute to the difference in the size of the 
corresponding nanoparticles. 
The concentration of the nanoparticles was estimated using freeze drying by determining the 
dry weight of the nanoparticles in 1 mL of suspensions. The results showed that PEGylated 
nanoparticles were more concentrated than both thiolated and POZylated nanoparticles 
(Table 1). These concentration estimates were used to quantify the free thiol contents of the 
nanoparticles.  
In this study, all three types of silica nanoparticles (thiolated, PEGylated and POZylated) 
were labelled with a fluorescent marker, by reacting them with FMA (Fig. S1 and S2). The 
fluorescent molecules were covalently bound to the nanoparticles via thiol-ene click reaction 
between the thiol groups of the nanoparticles and the vinyl groups of FMA. Fluorescent 
labelling enabled facile quantification of the nanoparticles on the surface of rat intestinal 
mucosa, with virtually no change in the particle size (see Table 1 and 2). In addition, no signs 
of aggregation or flocculation was observed for both fluorescently labelled and unlabelled 
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particles during the study (ca. 6 months). This indicates that FMA imparted a characteristic 
fluorescent signal to the particles without impairing the colloidal stability of the suspensions. 
Ellman’s assay showed a statistically significant difference in free thiol content among all 
three types of nanoparticles (p ˂ 0.05). Free thiol content decreased in the order of thiolated > 
PEGylated > POZylated nanoparticles (Table 1). This result indicates functionalisation of 
both PEGylated and POZylated nanoparticles, since PEGylation and POZylation were 
expected to replace free thiol groups with the corresponding polymers. The calibration curve 
used in the Ellmans’s assay is shown in Fig. S3. 
Table 2 
Properties of fluorescently labelled thiolated, PEGylated and POZylated silica nanoparticles 
(for fluorescence measurement, nanoparticles were diluted with PBS pH 7.4, 1:1,600), mean 
± SD, n = 3. 
Types of 
particles 
Size (d-nm) PDI Max. emission 
(nm) 
Max. intensity          
(a.u.) 
Thiolated 51 ± 1 
 
 
 
 
 
0.200 ± 0.018 512 411 ± 36 
PEGylated 71 ± 2 
 
 
0.106 ± 0.020 
 
 
512 233 ± 14 
POZylated 61 ± 3 0.117 ± 0.027 512 405 ± 38 
 
In agreement with our previous study (Irmukhametova et al., 2012), TEM results show that 
thiolated nanoparticles aggregated and formed ‘necklaces’(Fig.  2). A possible reason for the 
aggregation is disulfide bond formation between the nanoparticles, facilitated by drying 
during TEM sample preparation. In contrast, the TEM images of PEGylated and POZylated 
nanoparticles did not show any sign of aggregation. This observation, together with the DLS 
data, confirm the presence of primarily non-aggregated PEGylated and POZylated particles in 
the samples. Thus, although the ξ-potential of both PEGylated and POZylated nanoparticles 
had significantly decreased compared to the parent thiolated nanoparticles (table 1), their 
colloidal stability seemed to have dramatically improved. In addition to the overall reduction 
in reactive thiol groups in PEGylated and POZylated nanoparticles, steric hindrance (i.e. 
shielding of remaining thiol groups by the hydrophilic polymeric shells on the particle 
surface) is believed to be a major contributing factor to the improvement of colloidal 
stability.  
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Fig. 2. TEM images of unlabelled thiolated (A), PEGylated (B) and POZylated (C) 
silica nanoparticles. Thiolated nanoparticles formed necklace-like structure whereas 
both PEGylated and POZylated nanoparticles were mainly individually distributed.   
 
 
FTIR spectra and TGA thermograms are shown in Fig. S4 and S5, respectively. These results 
were in agreement with our previous studies (Irmukhametova et al., 2012; Mansfield et al., 
2015; Mansfield et al., 2016).  
As shown in Fig.  S1, S2 and Table 2, PEGylated nanoparticles fluoresced less intensely (p ˂ 
0.05) than thiolated particles. This is most likely due to the screening effect of non-
fluorescent PEG on the surface of these PEGylated nanoparticles. However, POZylated 
nanoparticles showed similar fluorescence intensity compared to thiolated nanoparticles (p > 
0.05), which was significantly higher (p ˂ 0.05) than that of PEGylated nanoparticles. The 
shorter POZ chain length (50 repeating units) compared to PEG (113 repeating units) 
(Mansfield et al., 2015) potentially led to less fluorescence screening resulting in a higher 
fluorescence signal in the POZylated nanoparticles.  
3.2.pH-stability study 
Particularly for oral formulations, the broad pH range encountered following administration 
can jeopardise formulation stability. The pH along the GIT ranges from around 2 in the 
stomach, to 6-7 in the small intestine and about 8 in the colon. We therefore evaluated the 
stability of thiolated, PEGylated and POZylated silica nanoparticles over the pH range of 
1.5–9, in terms of particle size, PDI and ξ-potential. The initial pHs of the diluted thiolated, 
50 nm 20 nm 20 nm(C)(B)(A)
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PEGylated and POZylated silica nanoparticle suspensions were 5.93, 5.67 and 6.08, 
respectively. Thiolated and POZylated nanoparticles were stable over the pH range of 2.5-9 
as no change in their z-average size was observed. However, they aggregated at pH ≤ 2, 
resulting in a significant increase in particle size (z-average: 4.29 ± 0.78 µm for thiolated and 
6.84 ± 0.52 µm for POZylated nanoparticles) and a polydisperse system (Fig. 4-A, B and C). 
This aggregation was irreversible as particle size was not reduced when higher pH was 
restored. The aggregation of the particles at pH < 2 could be a result of Si-O-Si covalent bond 
formation between the nanoparticles, owing to the availability of SiOH groups on the 
surface of the particles (Irmukhametova et al., 2012). In contrast, PEGylated nanoparticles 
were stable over the entire pH range investigated (1.5-9), as they showed neither aggregation 
nor dissociation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. DLS average size (A), PDI (B) at different pH environments, particle size distribution 
at pH 1.5 (C) and ξ-potential of thiolated, PEGylated and POZylated silica nanoparticles in 
different pH environments (D), mean ± SD, n = 3. No error bars shown in (C). 
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The ξ-potential of the nanoparticles was lower at low pH than at high pH (Fig. 4-D). 
Thiolated nanoparticles, however, had a more positive value (20 ± 1 mV) compared to 
PEGylated and POZylated nanoparticles (-0.17 ± 5 mV and 2 ± 1 mV, respectively). The 
reduction in the ξ-potential could be due to the association of the negatively charged SiO-  and 
S- ions with positively charged H+ ions, resulting in neutral SiOH or SH (Dyab, 2012). 
Interestingly, at low pH (~1.5) both PEGylated and POZylated nanoparticles showed a lower 
ξ-potential than thiolated nanoparticles. This could be explained by the fact that a significant 
number of SH groups were already replaced by PEG or POZ and thus less SH were formed 
by the association of its anionic form (S-) with H+ ions. Furthermore, this association might 
only decrease the ξ-potential to neutral, unlike in the case with thiolated nanoparticles, where 
the presence of more SH groups resulted in a positive ξ-potential. 
3.3. Ex vivo mucoadhesion study 
In our method of evaluation of mucoadhesive properties, dilution of the nanoparticles upon 
washing with simulated body fluids could happen. Thus, the minimum detectable 
concentration of fluorescently labelled particles on the surface of rat intestinal mucosa was 
evaluated. The fluorescence of labelled particles was detectable even upon dilution by nearly 
60-fold (Fig. S6). This result is also important for future studies involving the monitoring of 
these fluorescent nanoparticles in the GIT following oral administration, as the particles are 
likely to be diluted by GI fluids. As shown in Fig. S6, there is a linear relationship (R2 = 
0.9968) between the concentration of thiolated nanoparticles and their fluorescence intensity. 
Using a wash-off technique (Ranga Rao & Buri, 1989; Nielsen et al., 1998)  in combination 
with fluorescence microscopy, the retention of fluorescently labelled nanoparticles on the 
surface of rat intestinal mucosa was studied.  This technique has been previously used to 
study the retention of various materials on different surfaces including animal tissues and 
plant leaves (Irmukhametova et al., 2011; Štorha et al., 2013; Cook et al., 2015; Mun et al., 
2016; Symonds et al., 2016b; Tonglairoum et al., 2016).  
Samples were applied on the surface of rat intestinal mucosa and then washed with phosphate 
buffer pH 6.8 over several cycles. The fluorescence intensity on the mucosa was monitored 
following each wash cycle (Fig. 5). Based on the linear relationship established between 
nanoparticles concentration and fluorescence intensity (Fig. S6), the amount of fluorescent 
nanoparticles remaining on the tissue was estimated. As both fluorophores (FMA and FITC) 
were covalently bound to the materials under study (nanoparticles, chitosan and dextran), it 
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can be justifiably assumed that the percentage of remaining fluorescence intensity was 
directly proportional to the percentage of remaining materials. However, this method is likely 
to underestimate the amount of labelled nanoparticles/macromolecules as they are diluted by 
phosphate buffer solution during the wash cycles. In addition, a portion of the 
nanoparticles/macromolecules may diffuse into the mucus layer, resulting in attenuation or 
even obliteration of the fluorescent signal. However, both these factors were excluded in this 
particular study and the % remaining of all nanoparticles, FITC-chitosan and FITC-dextran 
(positive and negative controls) were calculated as described in section 2.11. 
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Fig. 5. Exemplar fluorescence microphotographs showing retention of FITC-chitosan 
(postive control used as a mucoadhesive material), thiolated, PEGylated and POZylated silica 
nanoparticles and FITC-dextran (negative control used as a non-mucoadhesive material) on 
rat intestinal mucosa following wash-out with phosphate buffer solution at pH 6.8. The 
values of the normalised fluorescence intensity were inserted into the top right corners of the 
representative images (a.u.). After washing the fluorescent nanoparticles by certain amounts 
of phosphate buffer solution, the fluorescence intensity from thiolated nanoparticles were 
greater than both PEGylated and POZylated nanoparticles. The scale bar is 5 mm. 
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At the end of each wash cycle, the % of thiolated nanoparticles remaining was significantly 
greater (p ˂ 0.05) than FITC-dextran which was used as a non-mucoadhesive material 
(negative control) (Fig. 6). Several studies have reported the non-mucoadhesive nature of 
dextran, which is likely due to its non-ionic character leading to muco-inertness instead of 
mucoadhesion (Khutoryanskiy, 2011; Withers et al., 2013; Mun et al., 2016). Thiolated 
nanoparticles also showed better retention than both PEGylated and POZylated nanoparticles 
(p ˂ 0.05) (Fig. 6).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Fluorescence level of rat intestinal mucosa exposed to FITC-chitosan , thiolated, 
PEGylated and POZylated silica nanoparticles and FITC-dextran washed by phosphate 
buffer solution (100 mM, pH 6.8) (n = 3 using 3-4 rats, mean ± SD, “*” represents p < 
0.05). 
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FITC-chitosan (positive control) showed remarkably higher retention than FITC-dextran (Fig. 
6). Many studies have confirmed the adhesion of chitosan to the mucus layers of various 
surfaces, including the eye, stomach and urinary bladder, owing to its cationic nature and 
ability to form electrostatic and hydrogen bonds with mucus components (Sogias et al., 2008; 
Mun et al., 2016; Tonglairoum et al., 2016). Over the first 3 wash cycles, thiolated 
nanoparticles showed a similar retention profile to FITC-chitosan (p ˃ 0.05). However, at the 
end of each wash cycle, neither PEGylated nor POZylated nanoparticles showed any 
statistically significant difference compared to FITC-dextran (p ˃ 0.05). This similarity of 
PEGylated and POZylated nanoparticles with FITC-dextran was persistent until the end of all 
wash cycles. In contrast, POZylated and PEGylated nanoparticles showed significantly less 
mucoadhesion than FITC-chitosan starting from the first and second wash cycle, respectively. 
(p = 0.034 for POZylated, p = 0.01 for PEGylated nanoparticles) (Fig. 6).  
Mun et al. (2016) showed that about 80% of thiolated silica nanoparticles, and only about 
40% of PEGylated nanoparticles, remained on the surface of bladder mucosal tissues after 
washing with 10 mL artificial urine. In comparison, we found less retention for all three types 
of nanoparticles (thiolated: 21%, PEGylated: 11%, POZylated: 10%) after washing with the 
same volume of the bio-relevant fluid (Fig. 6). This is because porcine bladder mucus is 
much thicker (1.4 ± 0.5 mm) than rat small intestinal mucus (30.6 ± 8.8 µm). A thicker 
mucus provides deeper “interdiffusion and entanglement” between the mucoadhesive 
particles and the mucus chain. Thus, a longer contact time might be achieved and this 
probably makes more groups available for the formation of chemical bonds responsible for 
mucoadhesion (Varum et al., 2010).  
In addition to the method developed by Mun et al. (2016) to determine WO50, we propose to 
calculate WO70 of the formulations. WO50 and WO70 represent the volume of phosphate 
buffer solution required to wash out 50% and 70%, respectively, of the formulations from the 
rat intestinal mucosa. Calculation of WO70  is important as generally a greater amount of both 
thiolated and PEGylated nanoparticles were washed off from rat intestinal mucosa compared 
to urinary bladder mucosa (Mun et al., 2016). Similar differences in mucosal retention have 
also been reported by Irmukhametova et al. (2011), Mun et al. (2016) and Štorha et al. (2013) 
on bovine corneal and porcine urinary bladder tissues. A few studies reported the similarity 
of the thickness and the structure of the mucus of human GIT to that of porcine and showed 
some resemblance of the two (Varum et al., 2010, 2012). However, rat intestinal mucosa is an 
ex vivo model widely used to measure the oral absorption of drugs and evaluate the 
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mucoadhesion and/or mucus-penetration of various drug delivery systems including 
nanoparticles (Lehr et al., 1992; Keely et al., 2005; Dünnhaupt et al., 2011; Merchant et al., 
2014; Maisel et al., 2015; Oltra-Noguera et al., 2015; Lozoya-Agullo et al., 2016). 
Therefore, using WO70   allows the comparison of different nanoparticles in terms of their 
wash-off profiles. Table 3 shows that WO50 values for FITC-chitosan (1.9 mL) and thiolated 
nanoparticles (1.58 mL) are nearly double to those for PEGylated (0.95 mL) and POZylated 
nanoparticles (0.88 mL). The WO70 for FITC-chitosan could not be determined since a 
sizeable proportion (> 40%) of the formulation remained tenaciously on the intestinal mucosa 
withstanding the multiple washing cycles (Fig. 5 and 6). On the other hand, the WO70 for 
thiolated nanoparticles was approximately 3-fold higher than PEGylated and POZylated 
nanoparticles. This indicates that thiolated nanoparticles resisted a greater amount of wash 
buffer than both PEGylated and POZylated nanoparticles. WO50 and WO70 of both 
PEGylated and POZylated nanoparticles were close to that of FITC-dextran denoting the non-
mucoadhesive nature of these two types of nanoparticles (Table 3). 
Table 3 
Values of WO50 and WO70 for FITC-chitosan, thiolated, PEGylated and POZylated silica 
nanoparticles, as well as FITC-dextran in rat intestinal mucosa.  
Types of materials WO50 (mL) WO70 (mL) 
FITC-chitosan 1.90 NA 
Thiolated silica nanoparticles 1.58 5.26 
PEGylated silica nanoparticles 0.95 1.73 
POZylated silica nanoparticles 0.88 1.58 
FITC-dextran 0.76 1.32 
Polynomial fitting (6th order) was used to calculate WO50 and WO70, the values of R
2 were 
between 0.94-0.98, WO50 and WO70: volume of phosphate buffer solution required to wash 
out 50% and 70% of the formulations, respectively, NA: not applicable. 
The reason for the better retention of thiolated nanoparticles compared to PEGylated and 
POZylated nanoparticles was most likely the formation of disulfide bridges between the 
thiolated nanoparticles and cysteine-rich domains of mucosal layers, since these nanoparticles 
had a greater free thiol content than PEGylated and POZylated nanoparticles. Conversely, 
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PEGylated and POZylated nanoparticles were effectively removed after a few wash cycles 
probably due to less disulfide bridge formation by virtue of their lower thiol contents. 
As all 3 types of the nanoparticles used in this study were negatively charged, the discrepancy 
in their mucoadhesive properties is unlikely to be related to the difference in charge. 
According to the electronic theory of mucoadhesion, anionic particles do not show any signs 
of adhesion to mucosal surfaces, which are also negatively charged, as like charges repel. 
However, mucoadhesion can be the result of one or more mechanisms, including ionic 
interaction, covalent bonding, hydrogen bonding, hydrophobic interaction, wetting, 
adsorption, diffusion and entanglement (Smart, 2005). In addition, as the particles dispersed 
in water, the effect of dispersion media on the mucoadhesive properties of the particles was 
excluded. Finally, the mucoadhesion was studied at pH 6.8, which was close to the pH of the 
ultrapure water used to dilute the nanoparticles for DLS size measurement. From the DLS 
data (Tables 1 and 2 and Fig. 1 and 4), clearly the nanoparticles were stable at neutral pH and 
did not show any sign of aggregation. Therefore, their retention would not be due to their 
deposition on the mucosal surfaces and rather was due to their ability to form disulfide bonds 
with cysteine residues in mucus.  
Several studies have shown that decorating nanoparticles with PEG facilitates their diffusion 
or penetration through mucus barriers (Lai et al., 2007; Mun et al., 2014b; Maisel et al., 
2015). Lai et al. (2007) reported that PEGylation of conventional large polystyrene 
nanoparticles (200 and 500 nm) led to their rapid transport through fresh human 
cervicovaginal mucus (CVM) and their diffusion coefficient (Dc) in mucus was just 4 to 6-
fold smaller than in water. In contrast, the Dc of uncoated polystyrene nanoparticles in CVM 
was 2,400 to 40,000-fold lower than in water. POZ has been studied as an alternative to PEG 
for the development of mucus-penetrating nanomaterials (Khutoryanskiy, 2018). For 
instance, Mansfield et al. (2015) showed that POZylated silica nanoparticles diffused rapidly 
through porcine gastric mucosa. This effect might be related to the hydrophilicity of these 
polymers, resulting in reduced hydrophobic interactions between the hydrophobic 
nanoparticle cores and the hydrophobic domains of the mucus layer. Similarly, in this study, 
the PEGylated and POZylated nanoparticles showed less mucoadhesion than thiolated 
nanoparticles. Based on these and our previous findings, we postulate that the PEGylated and 
POZylated nanoparticles may diffuse through rat intestinal mucus and thus be mucus-
penetrating, which is a desirable property in some drug delivery applications. In other words, 
the fact that the PEGylated and POZylated nanoparticles exhibited less mucosal retention 
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may not diminish their importance as a drug delivery system relative to the more 
mucoadhesive thiolated nanoparticles. The selection of either mucoadhesive or mucus-
penetrating carriers depends on the drug being delivered, the mucosal surface being targeted, 
the mucus turnover rate, the presence of water, the disease state and the intended release 
profile. Generally, mucoadhesive nanoparticles are advantageous for ocular and intravesical 
drug delivery where lacrimation and urine voiding from bladder remove a substantial amount 
of the drug at the site of application/absorption. Mucus-penetrating carriers, on the other 
hand, are desirable in the design of oral drug delivery where deeper mucus gel penetration 
and a broader particle distribution through the absorptive epithelia are required (Mun et al., 
2014b; Maisel et al., 2015; Mun et al., 2016; Netsomboon & Bernkop-Schnürch, 2016).  
4. Conclusion  
In this study, we have investigated the pH-stability profiles of thiolated, PEGylated and 
POZylated silica nanoparticles and evaluated their mucoadhesive properties in rat intestinal 
mucosa. PEGylated nanoparticles showed similar size over a broad pH range (1.5-9). Also, in 
case of thiolated and POZylated nanoparticles, no change in size was observed at pH 2.5-9. 
Thiolated nanoparticles were mucoadhesive in rat intestinal mucosa ex vivo but to a lesser 
extent than our previous study in urinary bladder mucosa. These mucoadhesive nanoparticles 
can potentially be used to prolong drug release. PEGylated and POZylated nanoparticles 
showed less mucoadhesion which suggests better permeability through the mucus layer than 
the thiolated nanoparticles. This property may allow the particles to diffuse more easily 
through the mucus barrier to the deeper absorptive epithelia, leading to better absorption of 
the drugs.   
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